
Downloaded from: http://researchonline.lshtm.ac.uk/12645/

DOI: https://doi.org/10.1136/bmj.324.7337.611

Usage Guidelines:

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: Copyright the publishers
Effectiveness of smoking cessation initiatives

Efforts must take into account smokers’ disillusionment with smoking and their delusions about stopping

Editor—Our survey of a representative national sample of 893 smokers shows that most are disenchanted with smoking and claim that they would not smoke if they had their time again. Furthermore, most smokers overestimate the likelihood of stopping in the future and greatly underestimate how long it is likely to take.

When asked: “If you had your time again would you start smoking?” 83% of current smokers replied that they would not (70% men, 87% women). Those aged 45 to 64 were most regretful, 90% saying that they would not smoke given their time again. This may reflect the mounting distress of smoking related diseases becoming noticeable in themselves and among their peers. Given the supposedly carefree and rebellious image attributed to teenagers and young adults, young people were also very disenchanted with smoking: 78% of those aged 16 to 24 declared that they would not smoke given their time again.

We also tested expectations about stopping smoking in the future. We asked:

“Looking ahead, do you think you will still be smoking in 1 year’s time, or will you have given up?” Those who responded that they would still be smoking were asked the same question looking ahead to 2, 5, 10, and 20 years’ time. We checked how realistic smokers’ expectations about stopping were by using data from the health survey for England to look at the proportion of ever smokers that had stopped in the equivalent time periods looking back from now.

The figure shows a delusion gap—a sharp misalignment of expectations about the timing of successfully stopping and the experience of recent history, particularly in the near term—with 53% expecting to stop within two years, but only 6% managing this in recent history. Women were more likely than men to think that they would stop smoking by one year (45% vs 34%), and younger smokers were more optimistic than older smokers (47% of those aged 16-24 vs 15% of those aged over 64). Poorer smokers were less likely to think they would have given up by one year (93% among the poorest vs 47% among the most affluent).

Eighty per cent of smokers under 40 believe that they will have stopped within 20 years; on average they believe they will stop within three years. Recent history shows that only 46% of ever smokers are still smoking at the age of 60.

The widespread disaffection with smoking among smokers combined with their tendency to be deluded about how easy and quick it will be to stop justifies extra urgency in promoting chances to stop. No Smoking Day on 13 March 2002 is an important opportunity to help smokers take on a realistic view of the difficulties of overcoming nicotine addiction. It will prompt smokers to make a credible attempt at stopping so that they can live the life they would want if they had their time again.

Martin Jarvis principal scientist, Cancer Research UK
Health Behaviour Unit, University College London, Brook House, London WC1E 6BT
Doreen McIntyre chief executive, No Smoking Day London EC1N 7RJ
Clive Bates director Action on Smoking and Health (ASH), London EC2A 4HW


Smoking cessation services show good return on investment

Editor—As Raw et al state, many people around the world have been watching the United Kingdom’s smoking cessation services with admiration. We have seen clear evidence from research trials that treatment of tobacco dependence works and is highly cost effective, but the United Kingdom is the first country to try to implement treatment services nationwide. Some might have queried whether sufficient numbers would attend these new services and whether the success rates would be similar to those achieved in research centres. But 127 000 people making an attempt at quitting and 48% achieving short term abstinence is a remarkable achievement in one year.

The resultant cost (<£800 per life year saved) represents excellent value for money by any standards. In the United States, where much health care is paid for by private health insurance, health insurance companies look for a positive return on their investment in paying for services—that is, they look for cost savings later for dollars invested in treatment now.

Treating tobacco dependence produces a strong return on investment by reducing substantially the high costs of treating myocardial infarctions, cancers, premature births, and chronic respiratory diseases caused by smoking. Other positive effects of smoking cessation services include reducing employees’ time off work and reducing the number of young people taking up smoking as a result of copying their parents.

Health insurance companies in states such as Utah, California, and Minnesota have realised that treatments with a high return on
investment should receive increased investment. They are thus now expanding coverage (payment) for effective behavioural and pharmacological treatment services similar to those in the United Kingdom. For the NHS to set up such an exemplary service and then allow it to die by not continuing its funding would be truly scandalous. Now that the scheme has been shown to be so successful and has shown such a good return on investment, the minister for health should act to secure increased funding for these services in the long term.

Jonathan Foulds, associate professor
University of Medicine and Dentistry of New Jersey, School of Public Health, NJ 08890, USA
jonathan.foulds@umdnj.edu


Commentary: Iloprost for cholesterol emboli syndrome

The following letter was commissioned by the BMJ as a commentary to accompany the research pointer published on 2 February. Owing to a failure of our processes we did not publish the commentary alongside the article. We are therefore publishing it now with apologies to Professor Pusey and our readers.

In a recent research pointer Elinav et al describe four cases of cholesterol emboli syndrome treated with iloprost. Their main observations were improvement in distal extremity ischaemia in all cases and improvement in renal function in the one patient with acute renal impairment. Cholesterol emboli syndrome appears to be increasingly common, perhaps because of increased funding for these services in the long term.

Jonathan Foulds, associate professor
University of Medicine and Dentistry of New Jersey, School of Public Health, NJ 08890, USA
jonathan.foulds@umdnj.edu

1 Elinav E, Chajek-Segal T, Stern M. Improvement in cholesterol emboli syndrome after iloprost therapy. BMJ 2002;324:324-6. (2 February)

Deaths from chickenpox

Deaths from chickenpox in adults are decreasing

Editor—On the basis of death certificates from the Office for National Statistics from 1995 to 1997, Rawson et al conclude that deaths as a result of chickenpox are increasing in adults in England and Wales. More up to date figures from the Office for National Statistics, however, show that chickenpox mortality is decreasing in adults (from 32 deaths in 1996 to 18 in 2000—see figure (a)). Furthermore, the number of deaths from chickenpox and case fatality rates were significantly higher in 1995-7 (period of the analysis) than at any other period. The claim by Rawson et al that deaths in adults are increasing is therefore misleading.

The change in age related varicella mortality is the result of a shift in the age distribution of infection. Over the past two decades there has been an increase in cases in the youngest age group (possibly due to greater attendance of day-care)5. Over the same time period there has been a gradual increase in reported incidence in adults, which peaked in the late 1980s and has been falling since (figure (b)). This is broadly reflected in the gradual decline in deaths in adults during the past decade. The exception to this trend are 1996 and 1997—exactly the time period when Rawson et al performed their study. What has caused these large shifts in the incidence of varicella in adults is still largely unexplained.

Marc Brisson health economist
mbrisson@phls.org.uk
W John Edmunds health economist
jedmunds@phls.org.uk
Nigel J Gay mathematical modeller
ngay@phils.org.uk
Elizabeth Miller health economist
Immimisation Division, Public Health Laboratory Service Communicable Disease Surveillance Centre, London NW9 5EQ

We would like to thank the Office for National Statistics, and Douglas Fleming and the Birmingham Research Unit, Royal College of General Practitioners, for data.

Deaths from chickenpox (a) and annual consultation rate for chickenpox (b) in England and Wales, 1981-2000

Epidemiology of chickenpox in United Kingdom needs further investigation

Editor—Rawson et al highlight the potential severity of chickenpox. They say that the age distribution of chickenpox is changeable. But recent data from Scotland, England and Wales, and the United States show that the previous shift towards increased infection in older age groups has not been sustained.1 In recent years the trend has been towards decreased age at infection, with most cases now occurring among the group aged 1-4 years, rather than among children of school age.

Varicella vaccine is recommended for routine administration in the United States and Canada, among other countries, but its suitability for inclusion in the United Kingdom’s childhood immunisation programme is still being considered. Further work on the epidemiology of chickenpox in the United Kingdom is therefore now particularly important.

We have proposed a one year period of enhanced active surveillance for severe complications of varicella in children admitted to hospital throughout the United Kingdom and the Republic of Ireland, using the British Paediatric Surveillance Unit’s orange card scheme.2 The information gained, together with that of Rawson et al and others, would help to determine the advisability of a universal programme for the United Kingdom, and provide a baseline against which to evaluate its impact should it be adopted.

J Claire Bramley
Scottish Centre for Infection and Environmental Health, Glasgow G5 7LN claire.bramley@scieth.csatn.nhs.uk


Chickenpox associated morbidity may be long term

Editor—Rawson et al analysed deaths from chickenpox during 1995-7. It has previously been recorded that chickenpox in healthy adults has a 25-fold greater risk of complications than in children.3 Rawson et al show a significant mortality of chickenpox in England and Wales but do not address the question associated morbidity, an important issue when addressing the value of immunisation on a population. We recently performed a prospective study on respiratory function in adult patients with chickenpox admitted to a subregional infectious diseases unit in a United Kingdom hospital over a period of 29 months.4

Sixty six adult patients with chickenpox were admitted to hospital during this period. Four of whom were immunocompromised. Thirty eight patients fulfilled the study protocol and of these, 50% had radiological evidence of pneumonia (all immunocompetent).5 Three female patients required admission to intensive care unit, two of whom were pregnant. One patient presented with chickenpox encephalitis and five had superimposed bacterial skin infections.

Severe respiratory disease was associated with the presence of new respiratory symptoms, close contact with the index case, and a history of current smoking. On follow up at a year post-infection, 37% of patients with radiological pneumonia and 10.6% of those without pneumonia continued to have reduced single breath carbon monoxide transfer factor.

This effect was independent from the effect of smoking and may indicate permanent lung damage. It may therefore be that the morbidity relates not only to the acute infection and admission but also to longer term effects on the lung function, but the exact clinical relevance of our findings is uncertain at present. The study does, however, indicate that chickenpox causes significant morbidity in adults, which may be seen increasingly in the future. Accurate data on morbidity as well as mortality are required to inform the debate on the value of mass vaccination for chickenpox in the United Kingdom.

A H Mohns
clinical research fellow, infectious disease
Weston Education Centre, Guy’s, King’s and St Thomas’s School of Medicine, London SE5 8RS
Abdul.mohns@kcl.ac.uk

M W McKendrick
consultant physician
North Trent Department of Infection and Infectious Medicine, Royal Hallamshire Hospital Sheffield S10 2JF


Extracorporeal membrane oxygenation has important role

Editor—Rawson et al highlighted the potentially devastating effects of varicella infection, particularly the fact that adults in the United Kingdom are dying from it and these deaths are increasing in number.1 We know that the pneumonitis caused by varicella infection can lead to respiratory failure that is often the cause of death in these patients. Antiviral treatment may help in such patients, but only if their severely compromised physiology can be adequately supported until they recover.

Extracorporeal membrane oxygenation has been reported to be used successfully in cases of adult respiratory failure resulting from varicella pneumonia and we would like to bring the results of such intervention to the attention of Rawson et al.2-5 We have treated 15 adults with this procedure for confirmed varicella pneumonia in Leices- ter between August 1992 and December 1999. These 15 patients had a median age of 36 years (range 24-61), and were significantly hypoxic on referral with a ratio of arterial oxygen tension to fraction of inspired oxygen (PaO2/FiO2) of 8.09 kPa. The overall survival rate in these patients was 60%. Of the 11 patients, however, we treated with venovenous extracorporeal membrane oxygenation the survival rate was 75% (compared with zero for the four patients treated with venoarterial extracorporeal membrane oxygenation).

Letters
It seems likely, therefore, that this is a treatment that should be considered for fulminate varicella pneumonitis, but the numbers treated so far are too small to be sure of the effectiveness of this invasive treatment. To resolve this uncertainty, currently all such cases in the United Kingdom can be referred for entry into the CESAR (conventional ventilation or extracorporeal membrane oxygenation for severe adult respiratory failure) trial. Suitable patients will be randomised to receive either extracorporeal membrane oxygenation or continued conventional ventilation. Further details about the trial are available from www.cesar-trial.org.

Neil Roberts clinical extra corporeal membrane oxygenation fellow
Heartlink Extra Corporeal Membrane Oxygenation (ECMO) Centre, Glenfield Hospital, Leicester LE3 9QQ
NeilRob25@hotmail.com.

Giles J Peek lecturer in cardiac surgery Division of Cardiac Surgery gcj.peek@tue.nl

Nikki Jones research fellow in cardiac surgery Division of Cardiac Surgery nikki.jones@ul.tr.nhs.uk

Richard K Firmin consultant cardiac surgeon Division of Cardiac Surgery
Diana Elbourne head of medical statistics unit London School of Hygiene and Tropical Medicine, London School of Hygiene, WC1E 7HT


Secondary prevention of coronary heart disease

Ill defined inclusion criteria resulted in missed trials

Editor—The review by McAlister et al of secondary prevention programmes in coronary heart disease does not adhere to some of the major principals of good practice when conducting systematic reviews of the medical literature.1 These include a clearly defined research question, strict inclusion criteria so that the review can be replicated, an exhaustive search of the medical literature to find all relevant studies, and findings that can be interpreted easily by the reader and relate to clinical practice.

McAlister et al, at first glance, have chosen a huge area of the medical literature to review, encompassing both pharmacological and non-pharmacological interventions for the secondary prevention of coronary heart disease. On closer inspection, they say that it is their intention to review the literature concerned with disease management programmes for coronary heart disease. The definition of disease management programmes used is broad and is quoted as that proposed by Hunter et al as a combination of patient education, provider use of practice guidelines, appropriate consultation, and supplies of drugs and ancillary services; from the same source, Hunter et al also say that the spectrum of disease management extends from health promotion and disease prevention, through diagnosis, treatment and rehabilitation to long term care.1 This highlights the need to be absolutely explicit about the inclusion and exclusion criteria applied to a review in this area.

The trials included in the review are a mix of nursing and multidisciplinary team interventions, and also comprehensive cardiac rehabilitation programmes. Single modality rehabilitation programmes were excluded. Many trials of comprehensive cardiac rehabilitation—which should be considered admissible under the umbrella of disease management programmes—are missing from studies included in the review. A recent Cochrane review of exercise based rehabilitation for coronary heart disease, which was not picked up with the search strategy used by McAlister et al, cites at least 17 trials concerned with comprehensive cardiac rehabilitation that could have also been included in the review by McAlister et al.1 Including these trials in the current review results in a pooled odds ratio for all cause mortality of 0.87 (95% confidence interval 0.76 to 1.0).

A precise definition of disease management programmes is problematic, but using the authors’ own description, it seems that deficiencies in searching and application of inclusion criteria have resulted in a review that is difficult to interpret, is not replicable, and is potentially misleading.

Karen Rees research fellow in systematic reviews
Karen.Rees@bristol.ac.uk

Shah Ebrahim coordinating editor, Cochrane Heart Group
Shah.Ebrahim@bristol.ac.uk

Department of Cardiology, University of Bristol, Bristol BS8 2PR


Secondary prevention programmes may reduce overall mortality in high risk patients

Editor—In a meta-analysis of randomised trials, McAlister et al showed that secondary prevention programmes reduce admission to hospital and improve quality of life or functional status in patients with coronary heart disease, but their effects on patients’ survival remained uncertain.1 In primary prevention through lowering blood pressure, the absolute risk reduction is positively related to the overall risk profile of the patient.2-4 This implies that in combining patients at high and low risk the meta-analysis may have missed an effect in the latter group of patients. We reassessed the risk reduction in overall mortality by dividing the trials equally into two groups according to the proportion of death events in the control group, an indicator of how likely a patient may die in the absence of the prevention programmes. Heterogeneity in the risk difference and the odds ratio on a logarithmic scale was not significant (P=0.29) in the 10 trials that provided data on mortality: The mortality in the control group of the trials varied from 1.0% to 19.1%. Although the trial by Cupple et al showed a significant difference in mortality between the intervention and control group, neither the combined overall odds ratio nor the risk difference was significant. A risk of 7% divided the trials into two groups with an equal number. The combined risk difference, according to the fixed effect method, was 0.3% (95% confidence interval 0.7% to 1.3%) in the five low risk trials and −2.7% (−4.6% to −0.8%) in the five high risk trials.1 The two confidence intervals did not overlap, and the difference between the patients at high and low patients was significant (P=0.01). In addition, the combined odds ratio was also significantly lower in the high risk trials than that in the low risk trials (P=0.05).

These results suggest that secondary prevention programmes may reduce the overall mortality in patients at high risk but not in those at low risk. This reanalysis provides an example in which genuine clinical heterogeneity may still exist even when the overall heterogeneity is insignificant, heightening the importance of exploring the sources of heterogeneity in meta-analysis.5

Jin Tang associate professor in epidemiology and community medicine

Wilson Tam statistician Department of Community and Family Medicine, School of Public Health, Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region, China


Improved outcomes need to be defined

Editor—The paper by McAlister et al on secondary prevention programmes in coronary heart disease was highlighted in Editor’s choice and this week in the BMJ with the teaser that it showed that disease management programmes in coronary heart disease prevention can improve outcomes.1
What outcomes does the paper actually measure? Reinfarction rate? No. Overall mortality? No. McAlister et al point out that the study periods were too brief. Rate of admission to hospital? Debatable. Only two of the six reporting studies showed benefit and not to level of significance. Quality of life? Some. Again, significance not shown. Processes of care? This is an interesting one. McAlister et al suggest that this means the recording of risk factors and the prescribing of drugs.

The bottom line is the claim that improved outcomes means that the intervention groups are prescribed more drugs and that that is a good thing, claiming that the overall benefits of the drugs are already proved. Is this what improved outcomes really are? The consumption of a larger number of drugs to treat lipids, platelets, and blood pressure readings—where are the patients in all this? What is their experience? What about adverse reactions and side effects of the drugs? Were the improved outcomes of those who took cerivastatin and developed rhabdomyolysis?

We all want to achieve improved outcomes, but it would be more helpful if the BMJ were to be more specific in defining its terms. I know from this article that the described interventions lead to the prescribing of more drugs. I do not know whether these programmes are to be recommended.

Bob Leckridge

Glasgow Homoeopathic Hospital, Glasgow
G12 OYN
bolleckridge@virgin.net

---

**Advances in virtual reality are wide ranging**

**Editor**—McCloy and Stone have reviewed virtual reality in surgery. Providing an updated and clear picture of a field that changes and advances continuously is hard, and we would like to point out some other things that virtual reality offers to surgery. Applications are likely to determine advances not only in surgical training but also in operative planning, operative strategy, and techniques, as well as in telesurgery.

Systems that allow the assessment of psychomotor skills hold great interest for surgical training. We believe, though, that training in live tissues is still preferable, as it ensures interaction with organs and vessels, which is the core of surgical performance. Only by the future development of systems with full anatomical simulation of organs and operations will the need for training on animals be avoided.

Current applications of virtual reality in preoperative diagnostics include gastroscopy, bronchoscopy, and colonoscopy. Some authors have suggested that virtual colonoscopy may be better than barium enema for detecting polyps in the colon. Virtual colonoscopy has the additional advantage of allowing navigation in the bowel lumen and views of the mucosa from any angle, as well as the possibility of passing through stenosis and even crossing the colon wall into adjacent structures. These advantages and the ease of interpretation because of the wealth of imaging information might render virtual colonoscopy especially suitable in screening programmes for colorectal cancer.

The development of systems for 3D reconstruction of liver anatomy and hepatic lesions improves the localisation of tumours and operation planning. At the European Institute of Telesurgery we have developed fully automated software that, from computed tomographic scans and magnetic resonance images, quickly provides an accurate 3D reconstruction of anatomical and pathological structures of the liver as well as invisible functional information such as portal vein labelling and anatomical segment delineation (fig 1). Use of this method in over 30 patients has shown that automated delineation of anatomical structures is more sensitive and more specific than manual delineation by a radiologist.

Our group is also developing an augmented reality system allowing the 3D reconstruction of anatomical structures to be superimposed on the patient. For instance, 3D reconstruction of the vessels can appear on the visible surface of the liver through a virtual transparency (fig 2). A further step will then be to combine augmented reality and robotic systems to allow automation of surgical operations.

---

**News article on report about drug researcher was biased**

**Editor**—I wish to draw attention to an error in an article by Spurgeon. The drug company Apotex was sponsoring research into a new drug, deferiprone, and terminated a contract with one of the researchers because of several matters, but not as a result of her publishing her claims about the investigational drug.

The researcher declared her intention to publish her claims only after the company had terminated her contract. Had Spurgeon contacted other parties involved in this controversy he would have realised that the information on which he reported was inaccurate. Instead, he seems to have relied on a report commissioned by the Canadian Association of University Teachers, a union of teachers that was supporting the researcher.

Even if the union’s motives had been to establish the truth I question how the committee, selected by the union, could have investigated a complex matter by obtaining direct input from only one of the four major parties concerned. Though it may have had access to some documents, particularly those provided by the researcher in question, it did not have many of those belonging to the other parties.
Because of the lack of a balanced input the report seems merely to represent the researcher’s pleadings. Apotex agreed to provide input if the panel would investigate specific matters pertaining to the case, and on which it was based, but such assurances were not provided. This led Apotex to conclude that the assessment might not be truly independent—a fact borne out by the report.

Although the report acknowledges that three of the four parties did not participate in the inquiry, Spurgeon’s article failed to make this bias clear. The pro-researcher position of the report is evident throughout. For example, it failed to note that the researcher did not acknowledge in her publication that hers was a dissenting view among scientists who were studying the drug and that subsequently she and her supporters attempted to prevent publication of other scientists’ views of the drug.

The researcher’s claims regarding deferiprone were evaluated by the European Agency for the Evaluation of Medicinal Products in a special hearing, in addition to the standard assessment of safety and efficacy that is part of the regulatory process for the marketing authorisation of a new drug. After this evaluation the agency recommended the approval of deferiprone, a decision that was then authorised by the European Commission. This approval was particularly important because deferiprone was the first orally active iron chelator approved in Europe. Patients who were unable to tolerate the only other treatment (an injectable drug) now have an alternative.

Elie Betito director, public and government affairs
Apotex, 150 Signet Drive, Toronto, Ontario, Canada M9L 1T9

---

**Dysphagia**

**Causes of high dysphagia should be assessed by ENT surgeons**

**Editor—**There are serious omissions in the section on high dysphagia in Owen’s article on dysphagia. It seems ill considered to discuss the causes of upper oesophageal dysphagia without proper consideration of the possibility of head and neck malignancy. We acknowledge that the possibility of oesophageal malignancy is mentioned in the accompanying box, but no mention is made of head and neck cancer in the main text.

The incidence of head and neck cancer is increasing. Most patients with such cancer present with a combination of symptoms, of which cervical, or high, dysphagia is cardinal. It is imperative that patients presenting with high dysphagia are seen by a doctor experienced in assessing the upper aerodigestive tract, such as an ear, nose, and throat surgeon.

The suggestion that radiology—in particular, contrast studies—is of little value in the investigation of head and neck malignancy, as specialists, we visualise the pharynx and upper oesophagus with mirrors and a flexible laryngoscope and use rigid endoscopy under anaesthesia, which is the gold standard for investigation of this difficult area.

In summary, patients presenting with high dysphagia with no obvious neurological cause should be referred promptly to an ear, nose, and throat surgeon.

Kerry Haddow specialist registrar
kerryhaddow@hotmail.com

Gillian M MacDougall consultant
Malcolm A Burnard senior house officer
Department of Otorhinolaryngology, City Hospital, Edinburgh EH10 5SB

---

**Psychiatrists’ perspective is insufficient to root out racism**

**Editor—**Minnis et al in their vignette based report claim that racial stereotyping that occurs at the first psychiatric interview is insufficient to account for the inequalities in diagnosis of schizophrenia between black and white men in the United Kingdom. Their findings are not surprising. What people say and what they do are often two quite separate things. Respondents may have consciously or subconsciously over-compensated for their prejudices in the current climate of sensitivity to racial issues and because previous studies in psychiatry have used similar investigative formats.

The clinical evaluation that a psychiatrist performs is not simply a list of objective facts. It is a subjective account of an interaction between two people. This interaction is fashioned by the perceptions of the evaluator and the importance he or she chooses to give to certain information. The relative importance of different parts of the history depends on the culture of the speciality of psychiatry and the individual psychiatrist’s beliefs, understanding, value judgments, and prejudices. This reliance on preconceived beliefs is likely to be especially important at the first meeting with a patient. It is difficult for the assessor to acknowledge these beliefs, let alone for them to be elicited in a vignette study.

Studies have shown that, although initial pathways to psychiatric care are similar for different, British, ethnic minority groups, the subsequent care given to patients of African and Caribbean origin is more coercive and their service related outcome is poorer. There is something about the interaction of these groups of patients with psychiatric services that leads to their detriment.

Patients of African and African-Caribbean origin in the United Kingdom often have a negative experience of psychiatry. Unpublished work in our department has shown that this is more likely to be attributed to racism by the individual. A way forward may be to assess the service-users’ perceptions of discrimination and use these to improve services. Attention to this may improve the therapeutic alliance and outcome. Racism is, however, a complex, multifaceted process and likely to affect the outcome of therapeutic interactions at the interpersonal, institutional, and community level.

The study by Minnis et al is a welcome start, but racism needs to be examined on several different levels and from a number of different perspectives if we are to produce a truly equitable service.

Apu Chakraborty specialist registrar in psychiatry
St Ann’s Hospital, London N15 3Th
apuchak@virgin.net

Kwame McKenzie senior lecturer in transcultural psychiatry
Royal Free and University College Medical School, Department of Psychiatry and Behavioural Sciences, London NW3 2PF
Management of Helicobacter pylori infection

Treatments of ulcers can be improved and over-reliance on proton pump inhibitors reduced

Editor—Harris and Misiewicz in their review of managing Helicobacter pylori infection take a balanced view of the contentious issues surrounding treatment in patients without ulcers.1 But several inconsistencies are apparent in their approach to patients with ulcers, for whom solid evidence for treatment is available.

Harris and Misiewicz advocate only two attempts at eradication in patients with duodenal and gastric ulcers; failure of the second attempt is followed by maintenance treatment with antibiotic drugs. Although the 50% success rate for one course of eradication treatment is ideal, combined data from randomised controlled trials suggest that eradication rates of 73–87% are more usual.2 In everyday practice, rates of 64% or lower may be expected, depending on the regimen and interest of the clinician.

After two courses of treatment, potentially one in eight patients may still be infected, and failure to persevere with eradication treatment depends on patients' treatment of the natural history of the disease by preventing recurrence and haemorrhage of ulcers. Continuous antisecretory treatment is less convenient, less effective, and more costly; strategies must therefore be constructed to improve overall eradication rates.

In the light of this need to optimise success, Harris and Misiewicz's bias towards treatments based on using proton pump inhibitors and reluctance to endorses ranitidine bismuth citrate is surprising. Ranitidine based triple treatments are at least equivalent, and in some cases significantly superior, to regimens based on proton pump inhibitors as initial treatment.3 Bismuth based regimens (either ranitidine bismuth citrate or colloidal bismuth) seem superior to others after an initial failure.4 In this situation, triple therapy with ranitidine bismuth citrate, tetracycline, and metronidazole produced significantly better eradication rates than the quadruple therapy with proton pump inhibitors and bismuth advocated by Harris and Misiewicz.5 Treatments based on ranitidine bismuth citrate are effective and equivalent in cost to those using proton pump inhibitors, but Harris and Misiewicz did not recommend their wider use.

Few data are available concerning third line treatments. After using regimens containing clarithromycin and nitromidazole, there is no logical combination. Although a combination regimen using proton pump inhibitors, rifabutin, and amoxicillin seems promising in this situation, treatment directed by endoscopy, culture, and sensitivity testing seems better than empirical choice.6 More than 98% of patients requiring H pylori eradication can be successfully treated using a three step algorithm, removing the need for continued drug treatment.7 Strategies for H pylori eradication should not be based merely on first line eradication rates but include further steps to maximise success in those who will definitely benefit from treatment.

Ian L P Beales
clinical senior lecturer in cell biology
School of Medicine, Health Policy and Practice,
University of East Anglia, Norwich, NR4 7TT
lbeales@uea.ac.uk

Competing interests: IB has received research funding from Astrazeneca and financial support and sponsorship for educational activities from AstraZeneca, Janssen-Cilag, and Wyeth. IB has investments in a number of unit trusts which have holdings in several pharmaceutical companies including AstraZeneca and GlaxoSmithKline.

1 Harris A, Misiewicz JJ. Management of Helicobacter pylori infection. BMJ 2001;323:1047-50. (3 November.)

Eradication treatment can be tailored in patients undergoing endoscopy

Editor—In their review of the management of Helicobacter pylori infection Harris and Misiewicz suggest that patients likely to have metronidazole resistant H pylori infection should be treated with non-nitromidazole containing eradication regimens.8 But prediction of resistance to antimicrobials in H pylori infection relies on the availability of resistance data in the given geographic area of practice. Few hospitals carry out sensitivity testing of H pylori, therefore local data are seldom available. In addition, although Harris and Misiewicz point out that metronidazole resistance is commoner in women and patients from developing countries, translation of this knowledge into prescribing practice is difficult with treatment of individual patients.

Our study of 1064 consecutive patients in Sheffield found to be H pylori culture positive at endoscopy showed metronidazole resistance rates to be 45% for women compared with 37% for men (odds ratio 1.48; 95% confidence interval 1.15 to 1.91). For patients >60 years resistance was 34% compared with 44% for patients <60 years (odds ratio 0.62; 0.48 to 0.8).9 A pragmatic approach to H pylori eradication may be to exclude metronidazoles from regimens.

This would not be advised, as metronidazole is a cheap and effective antibiotic when used in regimes to treat metronidazole sensitive strains. Also, increased use of clarithromycin, as a replacement for metronidazole, is likely to result in more disruption and induction of resistance in host microflora and thereby reduce the efficacy of macrolides in the treatment of other infectious conditions.10

Culture and sensitivity testing of H pylori is well established and requires few special facilities. As Harris and Misiewicz discuss management of H pylori after endoscopy, it seems appropriate to recommend taking an additional biopsy at the time of procedure for microbiological culture. The patients could be treated with proton pump inhibitors if indicated, while sensitivity results are obtained (about one week), and then prescribed a specific, effective eradication regimen. In this era of increasing resistance to antimicrobials optimisation of treatment is of paramount importance in clinical practice.

Helena K Parsons
research fellow in infection and immunity
h.k.parsons@shef.ac.uk

David S Sanders
research fellow in gastroenterology
Martyne J Carter
specialist registrar in gastroenterology
Alan J Lobo
consultant gastroenterologist
Gastroenterology and Liver Unit, Royal Hallamshire Hospital, Sheffield S10 3JJ

Competing interests: None declared.

Dental plaque is a potential reservoir of Helicobacter pylori

Editor—In their review of the management of Helicobacter pylori infection Harris and Misiewicz do not mention the potential reservoir of H pylori in dental plaque on teeth.11 Because this is a biofilm, no antibiotic will penetrate it, and if it carries the organism, it must be removed mechanically with oral hygiene, scaling, and root planing—exactly as for periodontal diseases caused by plaque micro-organisms.12

The effect of removal and control of dental plaque on the plaque reservoir of H pylori was shown clearly in a short study.13 Triple therapy alone (omeprazole, clarithromycin, and metronidazole) was wholly ineffective, but scaling followed by chlorhexidine mouthwash eradicated H pylori in 80–90% of patients. Everyone dealing with bacterial diseases should remember that if biofilms are involved, antibiotics alone are unlikely to be sufficient treatment. Similarly, the mouth rinses useless without the scaling.

Biofilm, like dental plaque, is a ready source for reinfection. They are complex communities of many bacterial species with
powerful defences against chemical and pharmacological threats, but some organisms may not gain a foothold in them because of bacterial antagonisms. This means that not all patients with *H pylori* infection will necessarily have the organism in their dental plaque, which may have misled some investigators in the past. Reinfection from plaque will also be subject to variable host defences and therefore not necessarily have the organism means that not all patients with periodontitis for medical practitioners. BMJ 2002;324:910–13. (5 November.) 4 Watts TLP. Periodontitis in practice. London: Martin Dunitz, 2000: 47–52.

Clinical databases can complement controlled trials

**Editor**—We were interested to read the article by Padkin et al on the serendipitous use of the database of the Intensive Care National Audit and Research Centre (ICNARC) to complement the results of clinical trials. There is at least one other such high quality database in Britain.

Since 1995 the audit group of the Scottish Intensive Care Society, with national funding from the Clinical Resource and Audit Group, has collected a similar dataset. We receive data from 100% of Scottish adult intensive care beds (in 26 units) and so can be certain that our findings are generalisable. Because of our defined geographical area we can provide a denominator for incidence figures.

We support the use of the data in the manner described by Padkin et al. We had also queried our data to obtain an approximation of the incidence of sepsis in Scotland, with similar results. We have found this type of information useful not only at a national level but also in giving a very approximate indication of the effects on local budgets.

We are aware of the limitations of such an analysis. Data collected during the first 24 hours of intensive care and structured for another purpose can only estimate the number of patients with sepsis and, as Padkin at al say, cannot identify the patient data on the incidence and outcomes of sepsis. We have used a similar approach in the past to identify the incidence of combined respiratory and renal failure and acute respiratory distress syndrome. We believe that undue reliability cannot be given to information gleaned from data gathered for another purpose and that such data, although useful, should be used as a starting point for more detailed studies.

Louie Penderleith consultant in anaesthesia and intensive care Western Infirmary, Glasgow G11 6NT louie.penderleith@wigmor@northglasgow.nhs.uk


Hospital revises its own data in government league table

**Editor**—The government has placed great emphasis on hospital league tables, although potential and real flaws have been identified. We therefore thought it was appropriate to review our hospital’s process, assessing the accuracy of the mortality data in general surgery and the respective groups.

The data submitted included several patients who had undergone procedures that were specifically excluded. In the non-emergency group this would have reduced the number of patient deaths from 32 to 24 and in the emergency group from 121 to 100. In addition, the government guidelines can be ambiguous in defining minor operations. It seems unreasonable to include diagnostic or palliative procedures such as paracentesis. Such exclusions would have further reduced the deaths from 24 to 20 in the non-emergency group, and from 100 to 89 in the emergency group. Overall reductions would have been 37.5% and 26.5% in the respective groups. We have been unable to calculate the potential change in our league table positions as the government’s demographic correction factors are not readily obtainable.

An independent review of the case records of all deaths was undertaken by a panel of clinicians. Areas of concern were identified in 28 out of 9380 patients who underwent a procedure. The criticism in most of these cases was a failure by junior staff to recognise significant physiological deterioration; as a result senior staff was not contacted. The benefits of using an early warning scoring system have been shown to identify these cases, and increased emphasis has been made to ensure that this method of assessment is used regularly in all patients. This in turn should ensure appropriate involvement of senior staff.

Most patients have little choice but to attend their local hospital. If it seems that any hospital is underperforming, it will produce an illogical fear in the public eye. Fears regarding standards of local healthcare may be exacerbated by inaccurate government statistics. Small numbers, dubious statistics, and classification errors lead to potentially large differences in the position in league tables.

We recommend that data for submission should be assessed by an appropriately clinically qualified individual and the published list of exclusion procedures should be clarified and regularly revised.

M M Wright consultant anaesthetist J G N Studley consultant general surgeon M Wilkinson consultant histopathologist James Paget Healthcare NHS Trust, Directorate of General Surgery and Urology, Surgical Specialities, Orthopaedics, and Accident and Emergency, Directorate Management Office, Gorleston, Great Yarmouth, Norfolk NR31 6LA


Death rates of surgeons should not be published

**Editor**—Surgical organisations seem generally to have accepted the proposal to publish the death rates of individual surgeons. As a physician of sorts, although soon to be deregistered, I stand amazed. Although surgeons have rightly questioned the validity of rates that depend predominately on the nature of the problem and on the previous health of the patient, rather than on individual surgical skill, that is not the main objection to the proposal. Consider its possible effects. Unless surgeons are to be cloned, a range of competence will be found in any group of surgeons, which may, or may not, be reflected in death rates, because of the confounding factors.

But even if the rates were a valid indicator of competence, what would result from their publication? Either nothing (which would be sensible), or a trend by referring doctors or choosing patients to pick the surgeons at the upper end of the list. If this second reaction were widespread, it would produce one group of surgeons who were overstretched, and also tempted to opt for “safer” patients and procedures in order to preserve their safety status, and another group of surgeons who were underemployed, and increasingly out of practice. The raw consumerist reaction to that (often exemplified in the press) might be, “Well, sack them.”

A gloomy picture, but I hope an unlikely one. From extensive experience, I have faith in the good sense of doctors and patients to discern that this proposal is a spin reaction to consumerism gone mad. I am optimistic enough to hope that the information generated by what will be a costly exercise will be largely ignored. But the best option is not to do it.

Douglas Black former chief scientist, Department of Health and Social Security Ironbridge, Telford TFS 7DW

Rapid responses

Correspondence submitted electronically is available on our website